TR201910572T4 - Anti-cd26 antikorları ve bunların kullanımları. - Google Patents
Anti-cd26 antikorları ve bunların kullanımları. Download PDFInfo
- Publication number
- TR201910572T4 TR201910572T4 TR2019/10572T TR201910572T TR201910572T4 TR 201910572 T4 TR201910572 T4 TR 201910572T4 TR 2019/10572 T TR2019/10572 T TR 2019/10572T TR 201910572 T TR201910572 T TR 201910572T TR 201910572 T4 TR201910572 T4 TR 201910572T4
- Authority
- TR
- Turkey
- Prior art keywords
- present
- moreover
- treatment
- antibodies
- provides
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 208000032467 Aplastic anaemia Diseases 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
Abstract
Mevcut buluş, CD26'ya bağlanabilen yeni antikorlar, ve bir ilaç olarak kullanımları ile ilgilidir. Dahası, mevcut buluş, Graft-versus-Host Hastalığının (GvHD) tedavisinde ve/veya önlenmesinde kullanıma yönelik, Aplastik Aneminin tedavisinde kullanıma yönelik ve/veya hematopoietik kök hücre transplantasyonundan sonra aşılamanın arttırılmasında kullanıma yönelik antikorları sağlamaktadır. Dahası, mevcut buluş, mevcut buluşun en az bir antikoru içeren, farmasötik bileşimleri sağlamaktadır, ayrıca parçaların bir kitini sağlamaktadır.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13425029.9A EP2767549A1 (en) | 2013-02-19 | 2013-02-19 | Anti-CD26 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201910572T4 true TR201910572T4 (tr) | 2019-08-21 |
Family
ID=48092884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/10572T TR201910572T4 (tr) | 2013-02-19 | 2014-02-19 | Anti-cd26 antikorları ve bunların kullanımları. |
Country Status (26)
Country | Link |
---|---|
US (2) | US9376498B2 (tr) |
EP (3) | EP2767549A1 (tr) |
JP (2) | JP6240195B2 (tr) |
KR (1) | KR101869589B1 (tr) |
CN (1) | CN104684931B (tr) |
AU (1) | AU2014220777B2 (tr) |
CA (1) | CA2874422C (tr) |
CY (1) | CY1121980T1 (tr) |
DK (1) | DK2864359T3 (tr) |
ES (1) | ES2738283T3 (tr) |
HK (1) | HK1205151A1 (tr) |
HR (1) | HRP20191277T8 (tr) |
HU (1) | HUE045150T2 (tr) |
IL (1) | IL237244B (tr) |
LT (1) | LT2864359T (tr) |
ME (1) | ME03753B (tr) |
MX (1) | MX357293B (tr) |
NZ (1) | NZ631111A (tr) |
PL (1) | PL2864359T3 (tr) |
PT (1) | PT2864359T (tr) |
RS (1) | RS59093B1 (tr) |
RU (1) | RU2662933C2 (tr) |
SA (1) | SA515360248B1 (tr) |
SI (1) | SI2864359T1 (tr) |
TR (1) | TR201910572T4 (tr) |
WO (1) | WO2014128168A1 (tr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11242399B2 (en) * | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
US10630229B2 (en) * | 2016-10-11 | 2020-04-21 | Kevin Stapleton | Panel mounting bracket with grounding mid-clamp and related methods |
KR101960414B1 (ko) * | 2016-11-11 | 2019-03-27 | 대한민국 | 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도 |
MX2020006488A (es) * | 2017-12-22 | 2020-12-10 | Adienne S A | Metodo celular cuantitativo para determinar la actividad biologica de un ligando anti-cd26. |
CN109709337B (zh) * | 2018-12-28 | 2021-09-14 | 江苏众红生物工程创药研究院有限公司 | 人cd26的免疫组化检测试剂盒及其临床应用 |
CN117120475A (zh) * | 2020-07-28 | 2023-11-24 | 阿迪安股份公司 | 特发性炎性肌病的治疗 |
WO2022238977A2 (en) | 2021-05-13 | 2022-11-17 | Adienne S.A. | Methods of treating dermatomyositis |
WO2022238978A1 (en) | 2021-05-13 | 2022-11-17 | Adienne S.A. | Methods of treating graft versus host disease |
CN118359716A (zh) * | 2023-01-18 | 2024-07-19 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
NL9400309A (nl) * | 1993-11-04 | 1995-06-01 | Eurogenetics Nv | Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. |
PT1241179E (pt) | 1998-04-15 | 2006-12-29 | Genentech Inc | Proteína humana possuindo actividade antiproliferativa in vitro |
EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
WO2002092127A1 (en) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
PL1844337T3 (pl) | 2005-01-24 | 2013-12-31 | Pepscan Systems Bv | Związki wiążące, związki immunogenne i peptydomimetyki |
BRPI0607486B8 (pt) | 2005-03-03 | 2021-05-25 | Immunomedics Inc | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. |
CN101282994B (zh) * | 2005-07-22 | 2013-09-18 | Y's治疗有限公司 | 抗cd26抗体及其使用方法 |
EA015735B1 (ru) * | 2005-09-14 | 2011-10-31 | Такеда Фармасьютикал Компани Лимитед | Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила |
US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
RU2331881C1 (ru) * | 2007-03-09 | 2008-08-20 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ определения риска развития атопических заболеваний у новорожденных детей |
CA2738485A1 (en) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
AU2011291651B2 (en) * | 2010-08-18 | 2016-01-14 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
-
2013
- 2013-02-19 EP EP13425029.9A patent/EP2767549A1/en not_active Withdrawn
-
2014
- 2014-02-19 EP EP14705767.3A patent/EP2864359B1/en active Active
- 2014-02-19 PT PT14705767T patent/PT2864359T/pt unknown
- 2014-02-19 HU HUE14705767A patent/HUE045150T2/hu unknown
- 2014-02-19 AU AU2014220777A patent/AU2014220777B2/en active Active
- 2014-02-19 CA CA2874422A patent/CA2874422C/en active Active
- 2014-02-19 EP EP19170670.4A patent/EP3536711A1/en not_active Withdrawn
- 2014-02-19 KR KR1020147035708A patent/KR101869589B1/ko active IP Right Grant
- 2014-02-19 TR TR2019/10572T patent/TR201910572T4/tr unknown
- 2014-02-19 WO PCT/EP2014/053243 patent/WO2014128168A1/en active Application Filing
- 2014-02-19 NZ NZ631111A patent/NZ631111A/en unknown
- 2014-02-19 CN CN201480002117.1A patent/CN104684931B/zh active Active
- 2014-02-19 ME MEP-2019-212A patent/ME03753B/me unknown
- 2014-02-19 LT LTEP14705767.3T patent/LT2864359T/lt unknown
- 2014-02-19 DK DK14705767.3T patent/DK2864359T3/da active
- 2014-02-19 ES ES14705767T patent/ES2738283T3/es active Active
- 2014-02-19 SI SI201431259T patent/SI2864359T1/sl unknown
- 2014-02-19 RU RU2014153440A patent/RU2662933C2/ru active
- 2014-02-19 PL PL14705767T patent/PL2864359T3/pl unknown
- 2014-02-19 MX MX2014014935A patent/MX357293B/es active IP Right Grant
- 2014-02-19 JP JP2015529076A patent/JP6240195B2/ja active Active
- 2014-02-19 RS RS20190938A patent/RS59093B1/sr unknown
- 2014-02-19 US US14/184,241 patent/US9376498B2/en active Active
-
2015
- 2015-02-16 IL IL237244A patent/IL237244B/en active IP Right Grant
- 2015-04-07 SA SA515360248A patent/SA515360248B1/ar unknown
- 2015-06-18 HK HK15105797.7A patent/HK1205151A1/xx unknown
-
2016
- 2016-05-31 US US15/169,386 patent/US10208126B2/en active Active
-
2017
- 2017-07-10 JP JP2017134896A patent/JP2017221205A/ja active Pending
-
2019
- 2019-07-17 HR HRP20191277T patent/HRP20191277T8/hr unknown
- 2019-07-22 CY CY20191100774T patent/CY1121980T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201910572T4 (tr) | Anti-cd26 antikorları ve bunların kullanımları. | |
CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
EA201400579A1 (ru) | Антитела к il-36r | |
TR201910103T4 (tr) | Anti-fcrn antikorları. | |
UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
EA201290590A1 (ru) | Модифицированные туберкулезные антигены | |
EA201370018A1 (ru) | Составы рифаксимина и их применение | |
EA202193044A2 (ru) | Способы лечения таупатии | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201390993A1 (ru) | Антитела к cd38 | |
EA201401204A1 (ru) | Антитела к il-23p19 | |
BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
MA37538A2 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
TR201910744T4 (tr) | Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. | |
EA201390660A1 (ru) | Модифицированные никотиновые соединения и связанные способы | |
CL2015001472A1 (es) | Composiciones y métodos para anticuerpos dirigidos epo. | |
EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
EA201590491A1 (ru) | Иммуногенная композиция | |
UA111340C2 (uk) | Антитіло, яке специфічно зв'язується з tnf-альфа людини | |
PE20160528A1 (es) | Anticuerpos | |
CL2012003458A1 (es) | Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico. | |
EA201390467A1 (ru) | Композиции антител и способы применения | |
EA201690992A1 (ru) | Антитела, специфичные к fcrn |